Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer
- 1 June 1998
- journal article
- alimentary tract
- Published by Elsevier
- Vol. 114 (6) , 1180-1187
- https://doi.org/10.1016/s0016-5085(98)70423-8
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.Journal of Clinical Oncology, 1995
- Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final ReportAnnals of Internal Medicine, 1995
- The Genetic Basis of CancerScientific American, 1995
- Association of p53 mutations with short survival in colorectal cancerGastroenterology, 1994
- Determination of Tumor Aggressiveness in Colorectal Cancer by K-ras-2 AnalysisArchives of Surgery, 1993
- Prognostic factors in colorectal cancerBritish Journal of Surgery, 1992
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990
- Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]JAMA, 1989
- Allelotype of Colorectal CarcinomasScience, 1989
- Concerted Nonsyntenic Allelic Loss in Human Colorectal CarcinomaScience, 1988